<?xml version="1.0" encoding="utf-8"?><rss version="2.0"><channel><title>Mayo Clinic Research news and Discovery's Edge</title><link>/rss/research-news</link><description>Find news related to research at Mayo Clinic.</description><language>en-US</language><item><title>Mayo Clinic study finds wearable data may help predict patient engagement in remote COPD rehabilitation</title><description>ROCHESTER, Minn. — Sleep data captured with a wearable device could help clinicians better tailor care by identifying patients with chronic obstructive pulmonary disease (COPD) who may need additional support to participate in pulmonary rehabilitation, according to new research published in Mayo Clinic Proceedings: Digital Health. COPD is a long-term lung disease that makes it hard to breathe after airways become inflamed and narrowed and mucus builds up. COPD can also make sleeping more difficult,&amp;hellip;</description><link>https://newsnetwork.mayoclinic.org/?p=412394</link><pubDate>Thursday, March 26, 2026</pubDate></item><item><title>Vitamin D linked to immune response to gut microbiome in inflammatory bowel disease</title><description>Vitamin D supplementation may help shape how the immune system responds to gut bacteria in people with inflammatory bowel disease (IBD), according to a Mayo Clinic–led study published in Cell Reports Medicine.</description><link>https://newsnetwork.mayoclinic.org/?p=412355</link><pubDate>Thursday, March 26, 2026</pubDate></item><item><title>A century of discovery: Mayo Clinic Proceedings marks 100 years of advancing medical research, education and practice</title><description>ROCHESTER, Minn. — For 100 years, Mayo Clinic Proceedings has helped shape the course of modern medicine — publishing discoveries that move from the page to the bedside and improve care for patients around the world. As the journal approaches its centennial in April 2026, Mayo Clinic is marking the milestone with events, exhibitions and special publications celebrating a century of scientific rigor, collaboration and impact. Rooted in the same spirit that drives Bold. Forward.,&amp;hellip;</description><link>https://newsnetwork.mayoclinic.org/?p=412072</link><pubDate>Monday, March 23, 2026</pubDate></item><item><title>Mayo Clinic study demonstrates safety, feasibility of delivering chemotherapy at home</title><description>JACKSONVILLE, Fla. — In a study published in NEJM Catalyst, Mayo Clinic researchers have demonstrated that chemotherapy can be safely delivered in patients' homes. The study evaluated Mayo Clinic's Cancer CARE Beyond Walls (Connected Access and Remote Expertise), a model that combines virtual care, remote patient monitoring and in-home clinical services to deliver cancer treatment outside traditional infusion centers. In the pilot study, a multidisciplinary team delivered 93 IV chemotherapy infusions to 10 patients in&amp;hellip;</description><link>https://newsnetwork.mayoclinic.org/?p=412027</link><pubDate>Thursday, March 19, 2026</pubDate></item><item><title>Mayo Clinic Minute: AI advances help care teams find hard-to-see colon polyps</title><description>Technology is changing how doctors detect colon cancer. New AI-enhanced imaging tools help physicians find subtle polyps that might otherwise be missed. Learn more from Dr. Michael Wallace, a Mayo Clinic gastroenterologist. Watch: The Mayo Clinic Minute https://youtu.be/BYxcD2rfBPo Journalists: Broadcast-quality video (1:09) is in the downloads at the end of this post.&amp;nbsp;Please courtesy: "Mayo Clinic News Network." Read the&amp;nbsp;script. Polyps in the colon can vary in size and shape. Some are more mushroom-shaped, but that's not always the case. &amp;hellip;</description><link>https://newsnetwork.mayoclinic.org/?p=411637</link><pubDate>Wednesday, March 18, 2026</pubDate></item><item><title>Mayo Clinic researchers use milk-derived nanoparticles to target aggressive bile duct cancer</title><description>ROCHESTER, Minn. — Mayo Clinic researchers have developed a promising new way to deliver treatment directly to cholangiocarcinoma tumors, a rare and aggressive bile duct cancer with limited treatment options, using milk-derived nanoparticles that act like guided delivery vehicles. The findings, published in JHEP Reports, point to a potential targeted genetic therapy designed to attack cancer cells while sparing healthy tissue. "One significant issue is the lack of medications that treat the specific alterations in&amp;hellip;</description><link>https://newsnetwork.mayoclinic.org/?p=411722</link><pubDate>Monday, March 16, 2026</pubDate></item><item><title>Mayo Clinic team takes quantum leap to win global competition with brain-signal model</title><description>Dr. Rickey Carter (left) and Dr. Charles Bruce (right) hold a first-place sign after Mayo Clinic’s team won the Berlin Quantum Hackathon on March 5, 2026. Photo by Hugo Paquin, Kipu Quantum. On a global stage in Berlin, surrounded by leading scientists and engineers in quantum computing, a Mayo Clinic team earned first place at the Berlin Quantum Hackathon 2026. The five-week hackathon challenged six finalist teams to prove that quantum computing — one of&amp;hellip;</description><link>https://newsnetwork.mayoclinic.org/?p=411604</link><pubDate>Wednesday, March 11, 2026</pubDate></item><item><title>Tomorrow's Cure: Inside EVLP - a revolution for donor organs</title><description>This&amp;nbsp;episode&amp;nbsp;of "Tomorrow's Cure"&amp;nbsp;explores&amp;nbsp;how&amp;nbsp;ex vivo lung perfusion (EVLP) breaks new ground as a procedure that evaluates lungs outside the body. This procedure could transform an unusable lung into a potential&amp;nbsp;lifesaver.&amp;nbsp;&amp;nbsp; Mayo Clinic&amp;nbsp;experts&amp;nbsp;John Haney, M.D.,&amp;nbsp;a&amp;nbsp;cardiothoracic surgeon,&amp;nbsp;and Brandi&amp;nbsp;Zofkie, associate vice president at Lung Bioengineering Inc.,&amp;nbsp;discuss increasing the viability of available lungs for transplant.&amp;nbsp;The pair explains&amp;nbsp;the differences in available organs like kidneys,&amp;nbsp;livers&amp;nbsp;and lungs.&amp;nbsp;Dr. Haney&amp;nbsp;says&amp;nbsp;lung transplant lists have taken a different shape than other organs.&amp;nbsp;"Currently,&amp;nbsp;there are about 3,300 lung transplants&amp;hellip;</description><link>https://newsnetwork.mayoclinic.org/?p=411589</link><pubDate>Wednesday, March 11, 2026</pubDate></item><item><title>Mayo Clinic researchers find combination therapy reduces effects of 'zombie cells' in diabetic kidney disease</title><description>JACKSONVILLE, Fla. — Mayo Clinic researchers have identified a drug-and-supplement combination therapy that is capable of reducing the harmful effects of senescent cells – also known as "zombie cells" – in diabetic kidney disease. In eBioMedicine, a publication of The Lancet, the team reported that the combination of the cancer drug dasatanib and a naturally occurring substance known as quercetin decreased inflammation and boosted protective factors in the kidney. Diabetic kidney disease affects more than&amp;hellip;</description><link>https://newsnetwork.mayoclinic.org/?p=411306</link><pubDate>Thursday, March 5, 2026</pubDate></item><item><title>Mayo Clinic researchers link Parkinson's-related protein to faster Alzheimer's progression in women </title><description>ROCHESTER, Minn. — Alzheimer's-related brain changes progressed up to 20 times faster in women who also had abnormal levels of a Parkinson's-related protein, according to a Mayo Clinic study published in JAMA Network Open. The same pattern was not observed in men. The findings suggest that when alpha-synuclein — a protein linked to Parkinson's disease — accumulates alongside Alzheimer's pathology, it may drive faster disease progression in women. That interaction could help explain a long-standing&amp;hellip;</description><link>https://newsnetwork.mayoclinic.org/?p=411086</link><pubDate>Wednesday, March 4, 2026</pubDate></item><item><title>Tomorrow's Cure: The quiet beginnings of leukemia</title><description>This&amp;nbsp;episode&amp;nbsp;of "Tomorrow's Cure" explores how a type of blood cancer, chronic lymphocytic leukemia (CLL), is hard to detect early in its development and how monoclonal B-cell lymphocytosis (MBL) may be a precursor to CLL. The discussion focuses on how genetics can help shape the understanding of how likely people are to develop CLL from MBL and the cell analysis that aids this discovery.&amp;nbsp; Mayo Clinic&amp;nbsp;experts&amp;nbsp;Sameer Parikh, M.B.B.S,&amp;nbsp;a hematologist, and&amp;nbsp;Susan Slager, Ph.D., a lymphoma researcher, join&amp;hellip;</description><link>https://newsnetwork.mayoclinic.org/?p=411321</link><pubDate>Wednesday, March 4, 2026</pubDate></item><item><title>Mayo Clinic researchers discover hidden brain map that may improve epilepsy care</title><description>Mayo Clinic researchers have identified a hidden "movement map" deep within the brain — a discovery that could help surgeons reduce side effects from epilepsy procedures and guide future treatments for speech and movement disorders.</description><link>https://newsnetwork.mayoclinic.org/?p=410881</link><pubDate>Wednesday, March 4, 2026</pubDate></item><item><title>Mayo Clinic researchers identify key DNA changes in the brains of people with Alzheimer's disease</title><description>Researchers have identified specific DNA-level changes in the brains of people with Alzheimer's disease.</description><link>https://newsnetwork.mayoclinic.org/?p=411302</link><pubDate>Tuesday, March 3, 2026</pubDate></item><item><title>Study: 1 dose of non-prescribed Adderall raises blood pressure, heart rate in healthy young adults</title><description>ROCHESTER, Minn. — A single 25 mg dose of a combination of amphetamine-dextroamphetamine salts (Adderall) can have measurable cardiovascular effects in healthy young adults, a Mayo Clinic study found. Researchers, whose findings are published in Mayo Clinic Proceedings, aimed to better understand how the stimulant affects those who use it without a medical prescription. "The primary objective of our study was to investigate how a single dose of Adderall acutely affects cardiovascular hemodynamics — blood&amp;hellip;</description><link>https://newsnetwork.mayoclinic.org/?p=411226</link><pubDate>Monday, March 2, 2026</pubDate></item><item><title>Study identifies potential immunotherapy strategy for early-stage prostate cancer </title><description>Researchers found that pairing a next-generation immunotherapy with standard hormone therapy before surgery may help overcome a long-standing barrier in early-stage prostate cancer treatment. </description><link>https://newsnetwork.mayoclinic.org/?p=411012</link><pubDate>Thursday, February 26, 2026</pubDate></item><item><title>Mayo Clinic collaborates on ARPA-H award to develop a bioprinted liver for acute liver failure</title><description>Induced pluripotent stem cell colony immunohistochemistry at 20 times magnification. Mayo Clinic is a collaborator on an Advanced Research Projects Agency for Health (ARPA-H) award for an innovative project accelerating the development of a bioprinted liver. The project is aimed at reducing shortages of transplanted livers and liver organ rejection in people with acute liver failure. The award that will be up to $28.5 million is in collaboration with Carnegie Mellon University, which will be&amp;hellip;</description><link>https://newsnetwork.mayoclinic.org/?p=410956</link><pubDate>Wednesday, February 25, 2026</pubDate></item><item><title>Tomorrow's Cure: Shortening the diagnostic journey</title><description>This episode of "Tomorrow's Cure" explores the dramatic changes happening in pediatric care thanks to whole genome sequencing. Hear from Whitney Thompson, M.D., assistant professor of medical genetics and pediatrics at Mayo Clinic, Stephen Kingsmore, M.D. president and CEO of Rady Children's Institute for Genomic Medicine, and Sean George, CEO of Inflection Medicine, as they discuss the life-changing feeling of identifying rare genetic diseases and giving patients a precise diagnosis.  In the recent past, a step-by-step approach once meant going through one&amp;hellip;</description><link>https://newsnetwork.mayoclinic.org/?p=410726</link><pubDate>Wednesday, February 25, 2026</pubDate></item><item><title>Brain may reinforce seizures during sleep, Mayo Clinic study suggests</title><description>The brain may inadvertently "learn" to have seizures by treating them like important memories to be stored, according to new research from Mayo Clinic. The study, published in the Journal of Neuroscience, found that after a seizure, the brain enters a deep sleep state that mimics memory storage. This "saves" the seizure's path like a normal memory, strengthening the disease. The findings suggest new opportunities to prevent epilepsy from worsening by targeting brain activity during the hours immediately following a seizure — a critical period when harmful brain changes may occur.</description><link>https://newsnetwork.mayoclinic.org/?p=410366</link><pubDate>Monday, February 23, 2026</pubDate></item><item><title>Mayo Clinic study identifies mechanism behind immunotherapy resistance in lung cancer</title><description>Getty PHOENIX — Mayo Clinic researchers and collaborators have identified a previously unrecognized way lung tumors weaken the immune system, helping explain why many patients do not respond to immunotherapy and pointing to a potential new approach to make those treatments more effective. The study, published in Cancer Immunology Research, focuses on regulatory T cells, immune cells that normally keep the immune system from becoming overactive. In lung cancer, researchers found these same cells can&amp;hellip;</description><link>https://newsnetwork.mayoclinic.org/?p=410851</link><pubDate>Thursday, February 19, 2026</pubDate></item><item><title>Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine</title><description>Strategic collaboration brings together Mayo Clinic's extensive clinical insights, genomic data and Platform architecture with Merck's artificial intelligence (AI) and machine learning (ML) research capabilities RAHWAY, N.J., and ROCHESTER, Minn. — Merck (NYSE: MRK), known as MSD outside of the U.S. and Canada, and Mayo Clinic, the world's top-ranked hospital system, today announced a research and development agreement to apply artificial intelligence (AI), advanced analytics and multimodal clinical data to support drug discovery and development.&amp;hellip;</description><link>https://newsnetwork.mayoclinic.org/?p=410795</link><pubDate>Wednesday, February 18, 2026</pubDate></item></channel></rss>